Denmark’s Again Executes One of Industrial Biotech’s Most Significant 2026 Consolidations

Introduction

Denmark-based industrial biotechnology company Again is emerging as one of the notable players in the rapidly evolving industrial biotech and carbon-utilization landscape in 2026. Rather than relying on conventional fossil-based chemical feedstocks, the company is developing a platform that uses industrial CO₂ as a raw material to produce valuable chemicals.

Again’s growth reflects a broader consolidation of technologies, partnerships, capital, and industrial infrastructure around gas fermentation, carbon utilization, and low-carbon chemical production. Its expanding network of industrial projects and strategic collaborations is positioning the Danish company as an important contributor to the next generation of chemical manufacturing.

Again’s Industrial Biotechnology Model

Founded from research connected to the Technical University of Denmark (DTU), Again has developed a biotechnology platform that combines biocatalysts, fermentation, and industrial engineering to convert waste CO₂ into useful chemical products.

The company's technology uses microorganisms to consume industrial CO₂ and convert it into acetate, which can serve as an intermediate for producing chemicals, fertilizers, and other industrial products. This approach aims to replace some conventional fossil or agricultural feedstocks while simultaneously utilizing carbon that would otherwise be released into the atmosphere.

The company describes its approach as combining AI-designed biocatalysts with waste CO₂, allowing the development and optimization of biological production routes more rapidly than traditional chemical development pathways.

From Startup Technology to Industrial Platform

One of the most important developments in Again’s story is its transition from laboratory research toward industrial-scale deployment.

Again's first facility, CPH-1 in Copenhagen, has been operational since 2023. The facility uses industrial CO₂ from a large wastewater treatment plant and has demonstrated the ability to capture and convert up to one tonne of industrial CO₂ per day.

This demonstration has provided Again with operational data and process experience that can support the development of larger commercial facilities.

The company's expansion is therefore not simply about developing another biotechnology process. It represents an attempt to create a repeatable industrial platform capable of connecting carbon-emitting facilities with chemical production.

Strategic Collaboration with Unibio

A major development in Denmark's industrial biotech ecosystem during 2026 has been the collaboration between Again and fellow Danish biotechnology company Unibio.

The two companies are working together on a new gas-fermentation demonstration platform designed to convert industrial waste gases—including CO₂, carbon monoxide, hydrogen, and methane—into low-carbon chemicals and materials. The project has received DKK 24.6 million from Innovation Fund Denmark, while the total project budget is approximately DKK 37 million.

The initiative is significant because it brings together complementary technologies and expertise. Unibio contributes its gas-fermentation and reactor technology, while Again brings its experience in converting industrial CO₂ into chemical products.

The collaboration could help establish Denmark as a testing ground for continuous gas-based bioproduction and industrial carbon utilization.

Why This Represents Consolidation in Industrial Biotech

The significance of Again's development goes beyond a single company or technology.

Industrial biotechnology has historically faced a major challenge: moving promising biological processes from laboratory environments into economically viable industrial production. The current direction of Again's strategy shows a greater emphasis on integration.

This integration brings together:

• Biological conversion technologies

• Industrial CO₂ and waste-gas sources

• Fermentation infrastructure

• Chemical manufacturing

• AI-assisted biotechnology

• Industrial partnerships

• Government-backed research funding

• Commercial offtake and distribution networks

By connecting these components, companies can move closer to creating complete industrial ecosystems rather than isolated biotechnology projects.

Expansion Beyond Denmark

Again is also expanding its industrial footprint internationally.

Its TXS-1 facility in Texas City, United States, represents the company's first commercial facility on U.S. soil. The project is designed to demonstrate the use of industrial CO₂ for producing chemicals at commercial scale. Again has partnered with HELM AG for product offtake and distribution, connecting the technology with chemical customers in regional and international markets.

The company is also involved in the NOR-1 project in Norway, which focuses on producing green acetone using Again's technology. The project has received support through a €43 million EU Horizon grant and is designed to utilize more than 10,000 tonnes of industrial CO₂ annually while targeting production of up to 4,000 tonnes of acetone per year.

These projects demonstrate how Again is attempting to move its technology from a Danish demonstration environment toward a broader international manufacturing platform.

Investment Has Supported Rapid Scale-Up

Capital investment has been another important component of Again's expansion.

The company previously raised $43 million in Series A financing, co-led by HV Capital and GV, Google's venture investment arm. Other participants included KOMPAS VC, Denmark's Export and Investment Fund (EIFO), CSC Leasing, ACME Capital, and Atlantic Labs. The financing brought Again's total funding at the time to approximately $100 million.

The funding was intended to support the development of larger production facilities and accelerate the international deployment of Again's decarbonization technology.

This illustrates an important trend in industrial biotech: investors are increasingly looking beyond laboratory breakthroughs and toward companies capable of demonstrating commercial-scale production, infrastructure integration, and customer adoption.

Implications for the Chemical Industry

Again's model could have broader implications for chemical manufacturers and industrial feedstock markets.

Traditional chemical production remains heavily dependent on fossil-derived carbon. By using waste CO₂ as a feedstock, carbon-utilization technologies could potentially create an alternative source of carbon for selected chemical products.

The impact could extend to areas such as:

• Sustainable chemical feedstocks

• Low-carbon acetate and derivatives

• Fertilizer-related production

• Specialty chemicals

• Carbon utilization

• Industrial decarbonization

• Regional chemical manufacturing

If technologies such as Again's achieve competitive economics at scale, they could change how manufacturers think about feedstock sourcing and carbon management.

Denmark’s Growing Industrial Biotech Position

Again's progress also reflects Denmark's broader ambitions in industrial biotechnology.

The country's research institutions, biotechnology companies, industrial partners, and government funding programs are increasingly working together to commercialize biological solutions for difficult industrial challenges.

The 2026 collaboration between Again and Unibio is particularly relevant because it aims to establish a platform for continuous gas-based bioproduction and strengthen Denmark's position in industrial biotechnology.

This creates a potentially valuable ecosystem in which companies can test technologies using real industrial gas streams, develop commercial processes, and build export-oriented solutions.

What Comes Next?

The next major test for Again will be commercial scalability.

Demonstrating that microorganisms can convert CO₂ into chemicals is only one part of the challenge. The technology must also achieve competitive production costs, reliable plant operations, consistent product quality, efficient feedstock utilization, and strong customer demand.

Again's modular approach is intended to shorten the time required to develop and deploy new production facilities. The company states that its platform is designed to move projects from development to operation significantly faster than conventional industrial approaches.

Success at this stage could determine whether Again becomes a specialized carbon-utilization company or evolves into a broader platform for biological chemical manufacturing.

Conclusion

Again's development in 2026 highlights a significant shift taking place within industrial biotechnology: the movement from individual laboratory innovations toward integrated industrial systems.

Through its CO₂ conversion technology, international projects, strategic partnerships, investment backing, and collaboration with Unibio, the Danish company is building an ecosystem around the production of chemicals from industrial emissions.

The broader significance lies in the possibility of turning waste carbon into an industrial resource. If Again and its partners can demonstrate that this model can operate economically at commercial scale, it could contribute to a new generation of chemical manufacturing in which biology, industrial infrastructure, and carbon utilization work together to replace parts of the traditional fossil-based production model.